Delving into the Latest Updates on Zhejiang Lianhui Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Neoplasms

Diagnostic radiopharmaceuticals

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	1
Small molecule drug	1

1. To demonstrate that in patients with a high incidence of lung cancer, when comparing the image interpretation of primary and metastatic lesions with reference to true standard, the sensitivity or specificity of SPECT/CT (99mTc-EC-DG) is non-inferior to PET/CT (18F-FDG). 2. To further demonstrate the safety of 99mTc-EC-DG in patients.

Start Date24 Apr 2024

Sponsor / Collaborator

Zhejiang Lianhui Biomedical Technology Co., Ltd.

[+1]

100 Clinical Results associated with Zhejiang Lianhui Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Lianhui Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Lianhui Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Lianhui Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data